قالب وردپرس درنا توس
Home / Business / Sinopharm said the effective rate of coronavirus vaccine is 79%

Sinopharm said the effective rate of coronavirus vaccine is 79%



The Beijing Institute of Biological Products, a subsidiary of Sinopharm, said in a statement on Wednesday that the interim analysis of the Phase III clinical trial showed that the vaccine is safe and that people receiving two doses of the vaccine will produce high levels of antibodies.

The company said it is seeking formal approval from Chinese regulators to distribute the vaccine to the public.

According to the controversial emergency use plan approved by the Chinese government, Sinopharm has developed a coronavirus vaccine and has managed hundreds of thousands of people.

According to the company’s chairman, by November, nearly 1 million people had received the Sinopharm vaccine, although he did not specify which of the company’s two vaccines they had received.

Although no details were provided, a statement issued on Wednesday said the vaccine meets the standards of the World Health Organization and China̵

7;s own regulatory agency, the National Medical Products Administration.

The efficacy of the Sinopharm vaccine is not as good as that of the vaccine developed by Pfizer-BioNTech and Moderna, which has an efficiency of about 95%. Russia’s satellite V vaccine has an effective rate of 91%.
And the vaccine has an effective rate of 79%, which is lower than the 86% of the same vaccine announced by the United Arab Emirates on December 9. The UAE is based on the results of an interim analysis of late-stage clinical trials conducted there in July. Since then, the vaccine has been approved for public use.
The effective rate of Sinopharm vaccine is 70% higher than the average efficiency developed by Oxford University and AstraZeneca. On Wednesday, the United Kingdom became the first country to approve the public release of the vaccine.

One step closer to mass launch

Sinopharm’s results were announced weeks after its global competitors announced. Due to the lack of details, it is not yet clear whether the information provided is sufficient to dispel doubts about the quality of Chinese vaccines.

Nevertheless, the statement may still pave the way for the large-scale promotion of the vaccine in China and globally.

A Chinese vaccination expert confirmed to CNN earlier this month that the country’s goal is to vaccinate 50 million people with the native Covid-19 vaccine before the Lunar New Year celebrations in February.
China has pledged millions of coronavirus vaccines to countries around the world.Ready to deliver them

China is ready to send hundreds of millions of doses to countries that have already conducted final trials of its leading vaccine candidate. Chinese leaders also promised that more and more developing countries will be given priority.

Analysts say Beijing is using the global movement as a soft power tool to try to repair any damage to its image due to its early handling of the coronavirus pandemic.

China has five coronavirus drug candidates from four companies and they have entered phase 3 clinical trials, which is the last and most important testing step before seeking regulatory approval. After largely eliminating the spread of the coronavirus within its borders, Chinese drugmakers had to go abroad to find places to test the efficacy of their vaccines. Together, they launched Phase 3 trials in at least 16 countries/regions.

Sinopharm’s two vaccine candidates are undergoing phase 3 trials in 10 countries (mainly in the Middle East and South America).

Liu Jingzhen, chairman of Sinopharm, said last month that dozens of countries have requested the company’s vaccines. He did not disclose the names of these countries or elaborate on their proposed dosages, but he said CNBG’s production capacity could exceed 1 billion doses in 2021.

Compared with Pfizer and Moderna, Sinopharm’s vaccines can be stored without freezing temperatures, making transportation and distribution easier-especially in developing countries that lack cold storage capacity.

CNN Beijing Bureau contributed to the report.


Source link